Navigation Links
Oncolytics Biotech(R) Inc. Announces Opening of Enrollment in Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
Date:5/25/2010

CALGARY, May 25 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced that it has opened enrollment in its Phase 3 trial examining REOLYSIN in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers. The Company had previously received approval from the U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) process and the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to conduct the trial in those countries, respectively. Oncolytics intends to conduct the first stage of the trial at approximately 25 centres in the U.S., U.K., and Belgium but may elect to add centres in additional countries.

"Opening enrollment in our first pivotal study in an important step forward in our increasingly late stage REOLYSIN clinical program," said Dr. Brad Thompson, President and CEO of Oncolytics. "We expect enrollment to ramp up over the next quarter as additional centres come on line as the trial progresses."

As previously disclosed, the randomized, two-arm, double-blind, multicentre, two-stage, adaptive Phase 3 trial will assess the intravenous administration of REOLYSIN with the chemotherapy combination of paclitaxel and carboplatin versus the chemotherapy alone in patients with metastatic or recurrent squamous cell carcinoma of the head and neck, or squamous cell cancer of the nasopharynx, who have progressed on or after prior platinum-based chemotherapy. All patients will receive treatment every three weeks (21 day cycles) with paclitaxel and carboplatin and will also receive, on a blinded basis, either intravenous placebo or
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Oncolytics Biotech(R) Inc. Announces Reovirus Research to be Presented at ASCO Annual Meeting
2. Oncolytics Biotech(R) Inc. Announces Phase I Colorectal Cancer Study
3. Oncolytics Biotech(R) Inc. Announces Publication of Phase I Clinical Trial Results in Clinical Cancer Research
4. Oncolytics Biotech(R) Inc. Announces First Quarter 2010 Results
5. Oncolytics Biotech(R) Inc. Announces Details of 2010 Annual Shareholder Meeting
6. Oncolytics Biotech(R) Inc. Completes Patient Enrollment in Phase I Portion of U.S. Phase I/II Recurrent Malignant Gliomas Clinical Trial
7. Oncolytics Biotech(R) Inc. Receives Approval from the U.K. MHRA to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
8. Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development
9. Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters Over-Allotment Option
10. Oncolytics Biotech(R) Inc. Announces Unit Offering
11. Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase I/II Trial Results in Advanced Solid Cancers with a Focus on the Head and Neck at the AACR-NCI-EORTC Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... ... August 27, 2015 , ... Capital Edge Consulting , a nationwide ... pleased to announce their ranking as one of the top 5000 companies listed on ... companies across the nation. , “It is truly an honor to be recognized as ...
(Date:8/27/2015)... 27, 2015 The National Necrotizing Fasciitis ... life—were saved by doctors at Vanderbilt University Hospital in ... NovaBay Pharmaceuticals and Dr. John Crew , director ... Seton Medical Center in Daly City, CA. ... breakthrough approach, pioneered by Dr. Crew, that had previously ...
(Date:8/27/2015)... , Aug. 27, 2015 HUYA Bioscience International ... of the Japan Society of HTLV-1, held this week ... The purpose of the Society is to promote research ... development of medical technology and research related to these ... "HUYA is proud to support this prestigious ...
(Date:8/27/2015)... ... 27, 2015 , ... METTLER TOLEDO's web-based EasyFinder™ ... choices to a manageable shortlist of bench and floor scales and terminals. Specifying ... best with the customer’s industry and application. , Side-by-side product comparisons and ...
Breaking Biology Technology:Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 2Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 3Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 3HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 3HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 4METTLER TOLEDO Updates Online Scale Selection Tool 2
... (Santa Barbara, Calif.) A team of physicists at UC ... many different colors. By aiming high- and low-frequency laser beams ... from their cores, accelerated, and then smashed back into the ... light simultaneously. Their findings appear in the current issue of ...
... 2012  Islet Sciences, Inc., (OTC.BB: ISLT) a biotechnology ... of patented technologies in the field of transplantation ... its subsidiary DiaKine Therapeutics Inc. received European patent ... be used to treat diabetes, atherosclerosis and other ...
... RIDGE, N.J., March 28, 2012  Regado Biosciences, Inc., a ... with active control agents, announced that David J. Mazzo, ... & Company,s 11th Annual Healthcare Conference at 10 a.m. ... Palace Hotel in New York City. The ...
Cached Biology Technology:UCSB Physicists mix 2 lasers to create light at many frequencies 2UCSB Physicists mix 2 lasers to create light at many frequencies 3Islet Sciences Announces DiaKine Therapeutics' Novel Diabetes, Atherosclerosis Drugs Receives European Patent Protection 2Islet Sciences Announces DiaKine Therapeutics' Novel Diabetes, Atherosclerosis Drugs Receives European Patent Protection 3Regado Biosciences, Inc. to Present at Needham & Company's 11th Annual Healthcare Conference in New York, NY 2Regado Biosciences, Inc. to Present at Needham & Company's 11th Annual Healthcare Conference in New York, NY 3
(Date:8/10/2015)... Germany , August 10, 2015 ... in Eye Tracking Technology for more than two decades, ... Platform for integration into all consumer display formats. The ... seamless integration of eye tracking into consumer tablets, laptops, ... reality smart glasses. Omnivision,s leading sensor technology contributes to ...
(Date:8/5/2015)... , August 5, 2015 ... & Access Management Market by Software, Services, Vertical (BFSI, Airport, ... & Geography - Global Forecast to 2020", published by ... Management Market globally into various segments. The global PIAM ... 2014 to $546.2 Million by 2019, at a CAGR ...
(Date:8/3/2015)... , Aug. 3, 2015 Synaptics, Inc. (Nasdaq: ... solutions, today announced that members of the executive management ... Pacific Crest Global Technology Leadership Forum on Tuesday, August ... will be held at the Sonnenalp Resort in ... presentation may include forward-looking information. An audio webcast of ...
Breaking Biology News(10 mins):SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4
... Innovative Vector Control Consortium (IVCC) and Syngenta announced ... new Actellic 300CS micro-encapsulated formulation demonstrate effective control ... for more than eight months. Developed ... evaluations by Syngenta and IVCC partner laboratories in ...
... 22, 2010 Scientists at The Scripps Research Institute and ... shed new light on the molecular mechanism that enables us ... stove. In addition to contributing to our knowledge of basic ... for conditions such as acute or chronic inflammatory pain. ...
... Tenn., April 22, 2010 -- Mimicking the human nervous system ... of a method developed at Oak Ridge National Laboratory to ... other properties that make them attractive to use as artificial ... make bundles with enough fibers to match that of a ...
Cached Biology News:IVCC and Syngenta reach key insecticide development milestone 2New Scripps Research and GNF study helps explain how we can sense temperatures 2New Scripps Research and GNF study helps explain how we can sense temperatures 3New Scripps Research and GNF study helps explain how we can sense temperatures 4New ORNL carbon composite holds promise for bionics 2